Elliott Settles With Advisory Board as Strategic Review Continues

The healthcare technology and consulting firm reached a deal with activist investor Paul Singer’s fund that ends the threat of a director battle-for now. Advisory Board on Friday reached a settlement with activist investor Elliott Management’s Paul Singer that ends the threat of a director battle-for now-as the healthcare technology and consulting firm continues to explore strategic alternatives, such as a sale.

ValueAct’s Ubben Disinvesting in the Market

Activist investor Jeff Ubben of ValueAct on Wednesday evening painted a negative picture of the markets, noting that he is disinvesting and has put about $3 billion into cash, even as corporations push for M&A. “We’re very late cycle,” Ubben told a Reuters conference on the future of shareholder activism.

New Crop of Activist Investors is on the Hunt

A Lazard review of activist campaigns for 2016 show that first time insurgent campaigns represented about a quarter of all activism for the year – a new record. Last month startup fund Gilead Capital settled a brewing director-election proxy fight with Landauer to add one dissident director to the therapeutics and analytical services company’s board.

Meet the New Wave of Insurgents

A Lazard review of activist campaigns for 2016 show that first-time insurgent campaigns represented about a quarter of all activism for the year – a record. Last month, startup fund Gilead Capital settled a brewing director-election proxy fight with Landauer to add one dissident director to the therapeutics and analytical services company’s board.

Animal rights activist Peta buys stake in Louis Vuitton

Animal rights pressure group Peta has bought shares in Louis Vuitton Moet Hennessey in order to pressure it to stop selling bags and other products made from exotic animal skins. The stake in the French luxury group will give Peta the right to attend shareholder meetings and question the board in front of other shareholders.